Key result
TRV027 boosts neonatal contractility, doubling peak twitch Ca2+ transients without increasing heart rate.
Why the study?
The treatment of pediatric heart failure remains a long-standing unmet medical need.
Does TRV027 improve cardiac contractility in neonatal and immature cardiac models?
Does TRV027 improve cardiac contractility in neonatal and immature cardiac models?
p-value: p=<0.05
TRV027 exerts a neonatal-specific, sustained positive inotropic effect without increasing heart rate or oxygen demand, suggesting potential utility as a targeted therapy for pediatric heart failure.
Should not change neonatal HF care; extends β-arrestin pathway data to immature myocardium and warrants translational studies.
The treatment of pediatric heart failure is a long-standing unmet medical need. Angiotensin II supports mammalian perinatal circulation by activating cardiac L-type Ca2+ channels through angiotensin type 1 receptor (AT1R) and β-arrestin. TRV027, a β-arrestin–biased AT1R agonist, that has been reported to be safe but not effective for adult patients with heart failure, activates the AT1R/β-arrestin pathway. We found that TRV027 evokes a long-acting positive inotropic effect specifically on immature cardiac myocytes through the AT1R/β-arrestin/L-type Ca2+ channel pathway with minimum effect on heart rate, oxygen consumption, reactive oxygen species production, and aldosterone secretion. Thus, TRV027 could be utilized as a valuable drug specific for pediatric heart failure.
No takes yet. Share an insight, caveat, or question.
Kashihara et al. (2020) studied Pediatric heart failure. TRV027 vs. Saline was evaluated on Cardiac contractility (ejection fraction and twitch Ca2+ transients) (p=<0.05). TRV027 caused a neonatal-specific, sustained positive inotropic effect, doubling the peak twitch Ca2+ transient amplitude and increasing ejection fraction without increasing heart rate.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: